Apellis updates SYFOVRE label to include rare retinal vasculitis risk; rate 0.01% per injection

Apellis Pharmaceuticals, Inc.

Updated USPI Warnings/Precautions and Postmarketing Experience sections to include retinal vasculitis with/without occlusion.
Estimated rate of retinal vasculitis remains rare at 0.01% per injection, based on over 120,000 injections administered as of Nov 18, 2023.
Label update pursued in collaboration with the FDA.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.